• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫功能低下儿童的泊沙康唑血药浓度监测。

Posaconazole Plasma Monitoring in Immunocompromised Children.

机构信息

Department of Pharmacy.

Research Centre.

出版信息

J Pediatric Infect Dis Soc. 2017 Nov 24;6(4):389-392. doi: 10.1093/jpids/piw087.

DOI:10.1093/jpids/piw087
PMID:28186550
Abstract

Plasma posaconazole exposure was assessed in 13 children who underwent a hematopoietic stem cell transplant. The median dosage was 12.5 mg/kg per day, divided into 3 doses. Of these 13 patients, 46.2% (6) and 30.8% (4) achieved concentrations higher than 0.7 and 1.25 mg/L, respectively. In children at high risk, a higher dosage might be needed to achieve target concentrations.

摘要

对 13 名接受造血干细胞移植的儿童进行了泊沙康唑血药浓度监测。中位剂量为 12.5mg/kg/天,分 3 次给药。在这 13 名患者中,分别有 46.2%(6 名)和 30.8%(4 名)达到了 0.7mg/L 以上和 1.25mg/L 以上的浓度。对于高危患儿,可能需要更高的剂量来达到目标浓度。

相似文献

1
Posaconazole Plasma Monitoring in Immunocompromised Children.免疫功能低下儿童的泊沙康唑血药浓度监测。
J Pediatric Infect Dis Soc. 2017 Nov 24;6(4):389-392. doi: 10.1093/jpids/piw087.
2
Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed-release tablet and intravenous posaconazole.延迟释放片和静脉用泊沙康唑治疗的儿童、青少年和青年患者中实现泊沙康唑治疗血药浓度所需的初始泊沙康唑剂量。
Pediatr Transplant. 2020 Sep;24(6):e13777. doi: 10.1111/petr.13777. Epub 2020 Jul 8.
3
Posaconazole in paediatric malignancy and haematopoietic stem cell transplant: dosing to achieve therapeutic concentration.泊沙康唑在儿科恶性肿瘤和造血干细胞移植中的应用:实现治疗浓度的剂量。
J Antimicrob Chemother. 2024 Jul 1;79(7):1493-1507. doi: 10.1093/jac/dkae099.
4
Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.泊沙康唑的血浆暴露量与异基因干细胞移植患者的肠道粘膜炎相关。
Eur J Clin Pharmacol. 2016 Aug;72(8):953-63. doi: 10.1007/s00228-016-2057-6. Epub 2016 Apr 11.
5
Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.泊沙康唑片用于造血干细胞移植术后儿科患者抗真菌预防的疗效、安全性及可行性
J Cancer Res Clin Oncol. 2017 Jul;143(7):1281-1292. doi: 10.1007/s00432-017-2369-7. Epub 2017 Mar 3.
6
Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后接受抗真菌预防治疗的儿科患者的泊沙康唑血药浓度。
Med Mycol. 2016 Feb;54(2):128-37. doi: 10.1093/mmy/myv087. Epub 2015 Oct 18.
7
Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.口服泊沙康唑在患有移植物抗宿主病的异基因造血干细胞移植受者中的药代动力学。
Pharmacotherapy. 2007 Dec;27(12):1627-36. doi: 10.1592/phco.27.12.1627.
8
Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.泊沙康唑治疗药物监测在癌症患儿和青年患者中的应用。
Ann Pharmacother. 2013 Jul-Aug;47(7-8):976-83. doi: 10.1345/aph.1R775. Epub 2013 Jun 4.
9
Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后的泊沙康唑浓度。
Transpl Infect Dis. 2013 Oct;15(5):449-56. doi: 10.1111/tid.12108. Epub 2013 Jul 25.
10
Posaconazole Tablet Formulation at 400 Milligrams Daily Achieves Desired Minimum Serum Concentrations in Adult Patients with a Hematologic Malignancy or Stem Cell Transplant.每日400毫克的泊沙康唑片剂制剂在患有血液系统恶性肿瘤或接受干细胞移植的成年患者中达到了所需的最低血清浓度。
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6945-6947. doi: 10.1128/AAC.01489-16. Print 2016 Nov.

引用本文的文献

1
Relationship between posaconazole concentrations and clinical outcomes in paediatric cancer and haematopoietic stem cell transplant recipients.泊沙康唑浓度与儿科癌症及造血干细胞移植受者临床结局之间的关系。
J Antimicrob Chemother. 2025 Apr 2;80(4):897-907. doi: 10.1093/jac/dkae473.
2
Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.免疫功能低下儿童侵袭性曲霉菌病治疗面临的挑战。
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0215621. doi: 10.1128/aac.02156-21. Epub 2022 Jun 29.
3
Dose Optimisation of Posaconazole and Therapeutic Drug Monitoring in Pediatric Patients.
泊沙康唑在儿科患者中的剂量优化及治疗药物监测
Front Pharmacol. 2022 Apr 19;13:833303. doi: 10.3389/fphar.2022.833303. eCollection 2022.
4
Evaluation of Posaconazole Dosing in Children and Young Adults: A Single-Center Review.儿童和青年成人泊沙康唑给药剂量的评估:一项单中心回顾
J Pediatr Pharmacol Ther. 2021;26(8):834-840. doi: 10.5863/1551-6776-26.8.834. Epub 2021 Nov 10.
5
Antifungal Prophylaxis with Posaconazole versus Fluconazole in Children with Neutropenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience.泊沙康唑与氟康唑用于异基因造血干细胞移植后中性粒细胞减少儿童的抗真菌预防:单中心经验
J Blood Med. 2021 Jul 30;12:679-689. doi: 10.2147/JBM.S319890. eCollection 2021.
6
Pharmacokinetics and Pharmacodynamics of Posaconazole.泊沙康唑的药代动力学和药效学。
Drugs. 2020 May;80(7):671-695. doi: 10.1007/s40265-020-01306-y.
7
Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis.第二代三唑类药物治疗侵袭性曲霉病和念珠菌病的临床药代动力学
Eur J Drug Metab Pharmacokinet. 2019 Apr;44(2):139-157. doi: 10.1007/s13318-018-0513-7.